Maresin-1 and maresin-2 as synovial fluid biomarkers in psoriatic, rheumatoid, and osteoarthritis
By
Sukru Demir
Bugra Can
Omer Esmez
Mustafa Ata Aydin
Sevval Yagmur Gencer
Furkan Bildirici
Süleyman Serdar Koca
İbrahim Sahin
Suleyman Aydin
July 14, 2026
Clinical Scorecard: Maresin-1 and Maresin-2 Levels in Synovial Fluid as Potential Biomarkers for Psoriatic Arthritis, Rheumatoid Arthritis, and Osteoarthritis
At a Glance
Category Detail
Condition Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis Key Mechanisms Maresin-1 and Maresin-2 as pro-resolving mediators in inflammation. Target Population Patients undergoing knee arthrocentesis for joint effusion. Care Setting Clinical assessment of synovial fluid biomarkers.
Key Highlights
MaR-1 levels significantly higher in PsA compared to RA. ROC analysis shows MaR-1 has an AUC of 0.815 for differentiating PsA from RA. Optimal cut-off for MaR-1 is 3.252 ng/mL with 68.2% sensitivity and 86.4% specificity. MaR-2 shows modest differences among groups. Higher MaR-1 levels are associated with PsA. Guideline-Based Recommendations
Diagnosis
Use MaR-1 levels to differentiate PsA from RA. Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with PsA, RA, and OA undergoing knee arthrocentesis.
Maresin-1 may serve as a biomarker for inflammatory activity.
Clinical Best Practices
Consider measuring synovial MaR-1 levels in patients suspected of PsA. Utilize ROC analysis for diagnostic performance evaluation of biomarkers. Related Resources & Content
